Currently 4 bullish, 1 bearish — becoming more polarizing.
Analysts are holding steady at 4 bullish to 1 bearish.
4 YouTube analysts cover Hims & Hers Health, Inc. (HIMS).
4 YouTube finance analysts have published research on Hims & Hers Health, Inc. (HIMS). Across their latest videos, their tracked takes split 4 bullish to 1 bearish, so the coverage reads as becoming more polarizing rather than a single consensus call. TickerReceipts groups every tracked take by stance and links each one back to the exact moment in the source video, so you can hear the argument in the analyst’s own words instead of a summary. The sharpest split right now is over Where do analysts disagree on HIMS?. None of this is our opinion or a price target: it is a synthesis of what independent YouTube analysts have actually said about HIMS, organized so you can weigh the bull and bear cases side by side and decide for yourself.
The clearest disagreement among YouTube analysts covering Hims & Hers Health, Inc. (HIMS) is over Where do analysts disagree on HIMS?. 4 tracked takes argue the bull side and 1 the bear side, and we keep both cases on the same page with the video receipt behind each one. We do not pick a winner or resolve the debate for you: each side links to the exact timestamp where the analyst makes the claim, so you can judge the reasoning yourself. Where an analyst has changed their stance over time, that flip is recorded too. The point of HIMS’s debate view is not to tell you who is right, but to surface the strongest version of each argument from independent YouTube research, side by side, with sources you can check.
The most recent research on Hims & Hers Health, Inc. (HIMS) comes from 4 YouTube finance analysts, currently split 4 bullish to 1 bearish. Each take below is a receipt: the analyst’s claim, the stance we tagged it with, and a link to the exact moment in the source video. We surface tier-1 analyst opinions first, then official filings and other context as that data lands. Nothing here is generated or paraphrased into a house view — it is the actual YouTube research that exists on HIMS, organized newest-first and by debate. Use it to catch up on what credible independent voices are saying, see where they line up and where they clash on Where do analysts disagree on HIMS?, and follow any claim back to its source before you act on it.
(speculative) Hims is trending above moving averages, entering the longevity/peptides business, with potential to squeeze higher to 35-40.
Hims is a laggard play with momentum building. Entry into peptides/longevity business could catalyze updates and a squeeze. Price target 35-40 based on bullish flag.
HIMS is a long-term buy-and-hold — buying around $19 worked, and it still sits on the long-term portfolio.
The KOL explicitly places HIMS into a long-term buy-and-hold portfolio, using the ~$19 area as the initial purchase zone. The current plan is to pay attention if the stock pulls back further, implying continued conviction.
HIMS looks weak because revenue is flattening and the company is losing money, and the KOL prefers waiting for a lower price zone before considering an entry.
HIMS is criticized for turning from profitable to losing money, which the KOL links directly to stock underperformance. The chart is also described as ugly with struggle near the high-20s/low-30s area, leading to a “wait for lower” guidance tied to potential buy zones.
No official filings surfaced for HIMS yet.
Sentiment on Hims & Hers Health, Inc. (HIMS) is not a static number — it moves as analysts publish, revise, and occasionally reverse their calls. The current balance is 4 bullish to 1 bearish, and the broader trend reads as becoming more polarizing. TickerReceipts records every stance change over time so you can see whether today’s split is a fresh shift or a long-standing standoff, and which analysts moved. The free view shows the current balance and the latest direction; the full stance timeline, each analyst’s track record, and how the Where do analysts disagree on HIMS? debate evolved are part of the time dimension. We never invent momentum: when there is no prior snapshot to compare, we say so rather than fabricate a trend.
